Management of Cefazolin-Induced Pancytopenia

Initial Assessment and Stabilization

The American College of Physicians recommends obtaining a complete blood count with differential and peripheral blood smear to characterize the severity of cytopenias and rule out other causes in patients with suspected cefazolin-induced pancytopenia 1, 2
A thorough review of the medication timeline is necessary, as cephalosporin-induced hematologic toxicity can occur after variable durations of therapy, and assessing for alternative causes such as viral infections, other medications, autoimmune disorders, and bone marrow pathology is crucial 2, 3

For severe anemia, the American Society of Hematology recommends transfusing leukocyte-reduced packed red blood cells to maintain adequate oxygen delivery, and using irradiated blood products for potential stem cell transplant candidates 1, 2
For severe neutropenia, the Infectious Diseases Society of America recommends implementing strict infection control measures immediately, monitoring temperature every 4 hours, and initiating broad-spectrum antibiotics such as piperacillin-tazobactam 4.5g IV q6h if fever develops 1, 2, 3
The American College of Clinical Pharmacy suggests considering filgrastim (G-CSF) 5 μg/kg/day subcutaneously until ANC >1000/μL to stimulate neutrophil recovery in patients with severe neutropenia 1, 3

The American Society of Clinical Oncology recommends monitoring complete blood count daily until a clear upward trend in all cell lines is established, and continuing infection surveillance with temperature monitoring every 4 hours in neutropenic patients 1, 2, 3

The American Society of Hematology suggests obtaining bone marrow aspiration and biopsy if recovery does not occur within 2-3 weeks after drug discontinuation, or if alternative diagnoses such as myelodysplastic syndrome, aplastic anemia, or hematologic malignancy are suspected 1, 2

The European Society of Clinical Microbiology and Infectious Diseases recommends not delaying empiric antibiotics in febrile neutropenia, and initiating broad-spectrum coverage immediately while awaiting cultures 1
The American College of Physicians advises not overlooking other potential drug culprits, and reviewing all medications including trimethoprim-sulfamethoxazole, azathioprine, and other agents known to cause bone marrow suppression 2, 3

The European Heart Journal suggests considering non-cephalosporin alternatives based on infection type and susceptibility patterns when selecting alternative antimicrobial therapy after cefazolin-induced pancytopenia 4